Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091646 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
A Phase 2 study of Seborrheic Dermatitis, sponsored by Arcutis Biotherapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 226
- Enrollment target
- 20
- Study locations
NCT04091646 is a Phase 2 study of Seborrheic Dermatitis that has completed, run by Arcutis Biotherapeutics. The registered enrollment target is 226 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT04091646, a Phase 2 study of Seborrheic Dermatitis, has completed, sponsored by Arcutis Biotherapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 226 participants
- Enrollment target
- 20
- Study locations
Study Summary
This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis.
Conditions Studied
Interventions
- DRUG Roflumilast Foam 0.3%
- DRUG Vehicle foam
Study Locations (20)
Texas
- Arcutis Biotherapeutics Clinical Site 13 - Arlington
- Arcutis Biotherapeutics Clinical Site 11 - Austin
- Arcutis Biotherapeutics Clinical Site 41 - College Station
- Arcutis Biotherapeutics Clinical Site 25 - Houston
Florida
- Arcutis Biotherapeutics Clinical Site 42 - Coral Gables
- Arcutis Biotherapeutics Clinical Site 24 - Miami
- Arcutis Biotherapeutics Clinical Site 12 - Tampa
California
- Arcutis Biotherapeutics Clinical Site 19 - Fremont
- Arcutis Biotherapeutics Clinical Site 21 - Santa Monica
Michigan
- Arcutis Biotherapeutics Clinical Site 40 - Clinton Township
- Arcutis Biotherapeutics Clinical Site 20 - Detroit
Illinois
- Arcutis Biotherapeutics Clinical Site 10 - Rolling Meadows
Indiana
- Arcutis Biotherapeutics Clinical Site 22 - Plainfield
Kentucky
- Arcutis Biotherapeutics Clinical Site 15 - Louisville
Maryland
- Arcutis Biotherapeutics Clinical Site 28 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 226 participants |
| Start Date | 2019-12-04 |
| Est. Completion | 2020-08-21 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091646
The ClinicalTrials.gov registry entry for NCT04091646 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 226 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcutis Biotherapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seborrheic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Roflumilast Foam 0.3% is the first listed.
NCT04091646 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Texas, Florida, California.
Frequently Asked Questions
What is clinical trial NCT04091646 about?
NCT04091646 is a clinical study titled "Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis". This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis.
What is the current status of trial NCT04091646?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 226 participants. The study started on 2019-12-04. Estimated completion is 2020-08-21.
What conditions does trial NCT04091646 study?
This clinical trial studies the following conditions: Seborrheic Dermatitis.
What interventions are being tested in trial NCT04091646?
The interventions under investigation include: Roflumilast Foam 0.3% (DRUG), Vehicle foam (DRUG).
Who is sponsoring clinical trial NCT04091646?
This trial is sponsored by Arcutis Biotherapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04091646 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.